Multiplexed immunofluorescence identifies high stromal CD68⁺PD-L1⁺ macrophages as a predictor of improved survival in triple negative breast cancer.

ABSTRACT: Triple negative breast cancer (TNBC) comprises 10-15% of all breast cancers and has a poor prognosis with a high risk of recurrence within 5 years. PD-L1 is an important biomarker for patient selection for immunotherapy but its cellular expression and co-localization within the tumour immune microenvironment and associated prognostic value is not well defined. We aimed to characterise the phenotypes of immune cells expressing PD-L1 and determine their association with overall survival (OS) and breast cancer-specific survival (BCSS). Using tissue microarrays from a retrospective cohort of TNBC patients from St George Hospital, Sydney (n = 244), multiplexed immunofluorescence (mIF) was used to assess staining for CD3, CD8, CD20, CD68, PD-1, PD-L1, FOXP3 and pan-cytokeratin on the Vectra Pola

SUBMITTER: Wang J 

PROVIDER: S-EPMC8566595 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature